ADMA Biologics, Inc. (ADMA) Stock: Price, Forecast & Analyst Target
ADMA Biologics, Inc. (ADMA) — MoonshotScore 97/100 (Exceptional band), calculated Nov 18, 2026. Price $13.17 (-1.27%), as of the Nov 20, 2026 trading session; market cap $2.92B.
Educational signal · not a buy or sell recommendation · How to read this
ADMA Biologics, Inc. · ADMA · NASDAQ
ADMA Biologics, Inc. is a biopharmaceutical company specializing in plasma-derived biologics for immune deficiencies and infectious diseases. The company develops, manufactures, and markets products like BIVIGAM and ASCENIV, along with operating plasma collection facilities.
Price as of Nov 20, 2026
Key Statistics
MoonshotScore v2 · ADMA Biologics (ADMA)
ExceptionalWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Elite quality, a strong balance sheet and elite growth, but a full valuation; the market is already moving on it. The score also carries a risk penalty for reported profit not backed by cash flow. Business Quality: Elite; Financial Safety: Sound; Valuation: Full; Growth Durability: Compounding; Momentum: Surging.
- EPS beat 3 of the last 8 reports
- Altman Z 8.72 · Piotroski F 5
- ROE 41.9% · ROA 22.4% · current ratio 6.04
Helping: business quality, balance-sheet strength, durable growth, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 95 | Exceptional | |
| 95 | Exceptional | |
| 95 | Exceptional | |
| 97 | Exceptional | |
| 97 | Exceptional | |
| 97 | Exceptional |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $13.17 | |
| Change on the day | -1.27% | |
| 52-week range | $7.21 – $20.46 | |
| Market capitalisation | $2.92B | — |
| Price / earnings (trailing) | 17.25 | |
| Shares traded on the day | 2.45M |
Price & events
Other perspectives
Council score for ADMA Biologics (ADMA): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
4 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 17, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Nov 17, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.
Readings on this page are from Nov 21, 2026, except a card that shows its own read date.
What is ADMA Biologics (ADMA), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. ADMA Biologics, Inc. (ADMA) is listed on NASDAQ. It employs 644 people and is led by Adam S. Grossman. The market values it at $2.92B.
What do the latest results show for ADMA Biologics (ADMA)?
Short answer · as of
Against analyst estimates the company has EPS beat 3 of the last 8 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Sep 2025 | $134M | $36M | $0.15 (diluted) |
| Q4 FY2025 | $139M | $49M | $0.20 (diluted) |
| Q1 FY2026 | $114M | $45M | $0.19 (diluted) |
| Q2 FY2026 | $124M | $38M | $0.16 (diluted) |
What are the financial strengths and risks for ADMA Biologics (ADMA)?
Short answer
The MoonshotScore pillars rate business quality, balance-sheet strength, durable growth, positive momentum as strengths. The distress and quality screens read Altman Z 8.72 · Piotroski F 5. Trailing ratios: ROE 41.9% · ROA 22.4% · current ratio 6.04.
What should you watch next at ADMA Biologics (ADMA)?
Short answer · as of
Current published price targets run low $18.00 · high $21.00 · consensus $19.50 · median $19.50 against a quoted price of $13.17 (as of Nov 20, 2026).
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
- The next earnings date is not yet scheduled in the calendar we read.
Checked against the records this page reads, on the dates shown above.
How does ADMA Biologics compare with its peers?
Short answer
ADMA Biologics's score ranks tied for 1st of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| ADMA Biologics (ADMA) — this page | $13.17 | $2.92B | 97 |
| $14.70 Nov 20, 2026 | $1.97B | 97 5-pillar Nov 18, 2026 | |
| $57.52 Nov 20, 2026 | $2.94B | 95 5-pillar Nov 18, 2026 | |
| $27.17 Nov 19, 2026 | $3.44B | 89 5-pillar Nov 18, 2026 | |
| $25.04 Nov 19, 2026 | $2.02B | 89 5-pillar Nov 18, 2026 | |
| $46.53 Nov 20, 2026 | $3.42B | 72 5-pillar Nov 18, 2026 | |
| $286.85 Nov 20, 2026 | $5.74B | 71 5-pillar Nov 18, 2026 | |
| $17.59 Nov 19, 2026 | $3.04B | 68 5-pillar Nov 18, 2026 | |
| $26.02 Nov 20, 2026 | $3.35B | 66 5-pillar Nov 18, 2026 | |
| $127.38 Nov 20, 2026 | $5.17B | 64 5-pillar Nov 18, 2026 | |
| $13.66 Nov 20, 2026 | $2.78B | 63 5-pillar Nov 18, 2026 | |
| $22.71 Nov 19, 2026 | $3.85B | 62 5-pillar Nov 18, 2026 | |
| $49.55 Nov 20, 2026 | $2.46B | 61 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $18.00 – $21.00
- Consensus target
- $19.50
- Median target
- $19.50
Consensus record · Captured .
Measured against a quoted price of $13.17 (as of Nov 20, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Nov 5, 2026
- Transactions
- 8
- Identified insiders
- 4
- Purchases
- 1
- Sales
- 2
- Other transactions
- 5
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held ADMA in their latest 13F filing, and what they did against the filing before it.
| Investor | Manager | 13F quarter | Portfolio weight | Value | Last quarter |
|---|---|---|---|---|---|
| Duquesne Family Office | Stanley Druckenmiller | Q3 2026 | 0.50% | $22.19M | Trimmed −20.5% shares |
| Fundsmith | Terry Smith | Q3 2026 | 0.13% | $16.54M | Held, unchanged |
| Bridgewater Associates | Founded by Ray Dalio | Q3 2026 | 0.04% | $9.79M | Added +143.3% shares |
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about ADMA Biologics (ADMA)?
What Investors Ask About ADMA Biologics (ADMA)
These answers are editorial: 1 of these 9 answers is drawn from the ADMA research dossier (written May 9, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for ADMA?
ADMA carries the MoonshotScore stated above — the Exceptional band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. ADMA Biologics, Inc. is a biopharmaceutical company specializing in plasma-derived biologics for immune deficiencies and infectious diseases.
Is ADMA a good stock to buy?
Stock Expert AI does not rate ADMA buy, sell or hold. ADMA Biologics, Inc. carries a MoonshotScore, in the Exceptional band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the ADMA stock price today?
The last price recorded for ADMA Biologics, Inc. (ADMA), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the ADMA price target?
The analyst consensus price target for ADMA Biologics, Inc. (ADMA), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
What do analysts say about ADMA stock?
Analyst sentiment on ADMA Biologics, Inc. is currently unavailable due to lack of source data. A comprehensive analyst consensus would typically include key valuation metrics such as price targets, earnings estimates, and growth projections.
What are the key factors to evaluate for ADMA?
ADMA Biologics, Inc. (ADMA) holds a MoonshotScore in the high range. To weigh it, compare the trailing P/E under Price & valuation with the analyst view under Analyst targets & estimates on this page. Strategic Acquisitions and Partnerships: ADMA can pursue strategic acquisitions and partnerships to expand its product portfolio, access new technologies, and enhance its market position. Not financial advice.
How frequently does ADMA data refresh on this page?
ADMA's price is the last quote we recorded, from the Nov 20, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven ADMA's recent stock price performance?
ADMA Biologics, Inc. (ADMA) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized expertise in plasma-derived biologics. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ADMA overvalued or undervalued right now?
The trailing P/E of ADMA Biologics, Inc. (ADMA) is listed under Price & valuation, and the analyst consensus target under Analyst targets & estimates, on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 9, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 18 figures on this page — 10 from Financial Modeling Prep (FMP), 7 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com